

B¹
as follows. FORWARD PRIMER (5' CCTG/CGTCATGTTTCATCTAC 3' (SEQ ID NO:18), and REVERSE PRIMER (5' CTCATAA/GGAA/GAC/TCTTGGAG/AGGG 3' (SEQ ID NO:19)). The PCR conditions used were 94°C for 30 seconds, 50°C for 1 minute and 72°C for 2 minutes. These conditions were used for 35 cycles of PCR. The resulting PCR products were separated on a 1% agarose gel and cloned into the TA clone kit (Invitrogen) according to manufacturers instructions. The resulting clones were taken for sequence analysis and separate clones were identified with identical sequence to the published rat brain II, heart, skeletal muscle and glial voltage-gated sodium channels.--

Page 16, delete the paragraph spanning lines 29 and 30, and insert the following therefor:

B²
--5' AGGGAGGTCACCGGCCTGAAA/C 3' (SEQ ID NO:20);
and 5 AGTGGATA/CGAGAA/CCATGTGGG 3' (SEQ ID NO:21).--

Page 22, delete the paragraph spanning lines 7-17, and insert the following therefor:

B³
--The octadecapeptide CNGDLSSLDVAKVKVHND (SEQ ID NO:22) relating to amino acid residues 1748 to 1765 of SNS_{2a} and the peptide EERYYPVIFPDERNC (SEQ ID NO:23) relating to amino acid residues 2 to 15 of SNS_{2a} were synthesised on a Biosearch 9500 peptide synthesiser using solid-phase Fmoc chemistry under conditions recommended by the suppliers. Cleaved peptide was purified by gel filtration and conjugated to purified protein derivative of tuberculin (PPD) using sulphy-SMCC. Dutch rabbits, presensitised against BCG, were immunised with the resulting conjugate emulsified in incomplete Freund's adjuvant. Rabbits were boosted at three week

B³ intervals and serum prepared from test bleeds 7 days after each injection. The specific antibody response was followed by indirect ELISA using free synthetic peptide as antigen. High titre antisera were used for further studies.--

Page 22, delete lines 21-26, and insert the following therefor:

--Fusion peptide 1 5' GATCGAATTCAAGGAGAAAATGTTTCAGGA 3' (SEQ ID NO:24) and 5' GATCGTCGACTCATTGGTCTGCTCAAGGA 3' (SEQ ID NO:25)

B⁴ Fusion peptide 2 5' GATCGAATTCGGCGGTGCCCTACCCACCTC 3' (SEQ ID NO:26) and 5' GATCGTCGACTCATTCCATTTCACCCCTT 3' (SEQ ID NO:27)

Fusion peptide 3 5' GATCGAATTCAAGCACAACTGTGGCCCCAA 3' (SEQ ID NO:28) and 5' GATCGTCGACTCACATTATGAAGTCTTCGC 3' (SEQ ID NO:29)--

Page 24, delete lines 14-19, and insert the following therefor:

--Antisense 1 5'-AGT ACC TCT CCT CCA TCT-3' (SEQ ID NO:30)

Mismatch 1 5'-AGT ACT CAT CCC TCA TCT-3' (SEQ ID NO:31)

B⁵ Antisense 2 5'-CAC CGG GTA GTA CCT CTC-3' (SEQ ID NO:32)

Mismatch 2 5'-CAC GCG CTA GTC ACT CTC-3' (SEQ ID NO:33)

Antisense 3 5'-GTC TTT GGA CTT CTT CCT-3' (SEQ ID NO:34)

Mismatch 3 5'-GTC TGG TGA CTC TTT CCT-3' (SEQ ID NO:35)--

Insert the attached Sequence Listing after the claims.